This Week in Aesthetics: January 18-22

January 22, 2021
Katie Hobbins

This week in aesthetics, a study examines tofacitinib to treat alopecia areata, Dr. Michael Kluska compares Renuvion (J-Plasma) versus Bodytite, and more.

This week in aesthetics, a study examines tofacitinib for the treatment of alopecia areata, Dr. Michael Kluska compares Renuvion (J-Plasma) versus Bodytite by InMode, MJH Life Sciences holds a webinar on COVID-19 variants, and the ASDS annual survey shows continued popularity of noninvasive procedures.

Tofacitinib for Treatment of Severe Alopecia Areata

A 2017 study examines the long-term efficacy of JAK 1/3 inhibitor, tofacitinib, for treatment of alopecia areata and its variants.

Device Review: Renuvion (J-Plasma) vs. Bodytite

In this monthly technology review, Dr. Michael Kluska compares Renuvion (J-Plasma) versus Bodytite by InMode, and how to choose which one suits your practice best.

Emerging SARS-CoV-2 Variants Webinar

MJH Life Sciences COVID-19 Coalition webinar on Jan. 26 will focus on COVID-19 variants emerging around the globe.

ASDS Survey Reports Nearly 14 Million Treatments in 2019

The American Society of Dermatologic Surgery releases its annual survey showing the continued popularity of minimally invasive and nonsurgical treatments.